Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer

Inclusion Criteria:

1. Signed informed consent to participate in the study;
2. Histopathological confirmation of triple-negative breast cancer;
3. Stage: clinical T1-T4, N0-3, M0;
4. Positive molecular genetic test for BRCA1\|2 gene mutation (PCR test or NGS result);
5. Age \> 18 years;
6. ECOG status 0-1.

Exclusion Criteria:

1. Prior administration of any systemic therapy for breast cancer;
2. Stage IV disease;
3. Severe uncontrolled chronic comorbidities or acute illnesses;
4. Renal dysfunction;
5. Age \> 70 years;
6. Presence of a second malignant tumor (except for previously cured malignancies);
7. Pregnancy or breastfeeding;
8. Negative molecular genetic test for BRCA1\|2 gene mutation